No quarterly revenue total was found in Dyne Therapeutics, Inc.'s SEC filings.
Dyne Therapeutics, Inc. (DYN) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$179.5 million. As of Sep 30, 2026 it held $1.1 billion in cash and investments and $218.9 million in total debt.
Revenue
—
Net income
$-193.55M
-79.1% vs year-ago quarter
Operating cash flow
$-177.49M
-95.5% vs year-ago quarter
Free cash flow
$-179.50M
-96.9% vs year-ago quarter
EPS
$-1.06
-39.5% vs year-ago quarter
Dividend per share
None
Shares outstanding
187.39M
+31.2% vs year-ago quarter
Net cash
$915.51M
Q3 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- DYN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Waltham, MA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1818794
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$197.1M | -$181.7M | -$125.3M | -$116.1M | -$113.9M |
| Net income | -$193.6M | -$178.6M | -$120.9M | -$112.0M | -$108.0M |
| Diluted EPS | -$1.06 | -$1.08 | -$0.73 | — | -$0.76 |
| Operating cash flow | -$177.5M | -$130.3M | -$144.9M | -$111.8M | -$90.8M |
| Free cash flow | -$179.5M | -$131.8M | -$145.1M | -$112.3M | -$91.2M |
| Total assets | $1.2B | $994.0M | $1.1B | $1.2B | $867.1M |
| Total liabilities | $303.9M | $291.9M | $214.9M | $214.8M | $175.3M |
| Stockholders' equity | $930.9M | $702.2M | $865.1M | $972.1M | $691.8M |
| Cash and investments | $1.1B | $898.5M | $972.2M | $1.1B | $791.9M |
| Total debt | $218.9M | $219.2M | $168.7M | $169.2M | $120.5M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations
|
Nov 5, 2026 | Nov 5, 2026 |
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 29, 2026 | Sep 29, 2026 |
| 8-K |
Current report
Results of operations
|
Jul 29, 2026 | Jul 29, 2026 |
| 10-Q | Quarterly report | Jul 29, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Material agreement, Other events
|
Jul 22, 2026 | Jul 21, 2026 |
All 796 Dyne Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.